The World's First-in-Class Intrauterine Drug-Eluting System SHANGHAI , Aug. 23, 2024 /PRNewswire/ -- Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun ( Shanghai ) Biotechnology Co., Ltd.
("YPR"), has received approval in China (G.X.Z.
Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a randomized controlled clinical trial that demonstrated Corina's superior efficacy compared to the standard-of-care.
Corina is a first-in-class treatment focused on promoting female reproductive health through the prevention of intrauterine re-adhesion risk post TCRA, and the improvement of endometrial growth. Intrauterine adhesions (IUA) are the formation of scar tissues in the endometrial cavity as a result of damages to the endometrial basal layer of the uterus, which leads to the partial or complete occlusion of the cervical canal and uterine cavity. Clinically, IUA can cause a range of symptoms such as reduced menstrual flow, amenorrhea, infertility and recurrent miscarriage – thereby posing a serious threat to the reproductive health of women of childbearing age.
Currently, the incidence rate of IUA in China remains high, and continues to grow due to an increased number of intrauterine interventions. Research in this field show the incidence rate of IUA in China to be as high as 25% in women who have had prior abortion or cure.